iSERA Lifescienc

Which are the latest news on iSERA Lifescienc?

Why is iSERA Lifesciences Ltd falling/rising?

As of 05-Sep, the stock price of iSERA Lifesciences Ltd is Rs. 143.90, unchanged from the previous session. Despite significant long-term gains, concerns about negative book value, stagnant profits, and declining investor participation indicate potential risks for investors.

As of 05-Sep, the stock price of iSERA Lifesciences Ltd is currently at Rs. 143.90, showing no change from the previous trading session. Despite this stability in price, the stock has demonstrated significant volatility and performance trends over various periods. Year-to-date, the stock has risen dramatically by 747.47%, and over the past year, it has surged by an astonishing 2961.70%. These impressive returns contrast sharply with the broader market, as the Sensex has declined by 10.21% year-to-date and 5.21% over the past year.<BR><BR>However, there are concerning factors that may indicate why the stock could be viewed as risky. The company has a negative book value of Rs. -0.11 crore, which suggests weak long-term fundamental strength. Additionally, while the stock has performed well in terms of price appreciation, its profits have only increased by 14% over the past year, raising questions about sustainability. The company's operating profit has been stagnant at 0% over the last five years, and recent quarterly results showed a lowest PBDIT of Rs. -0.34 crore.<BR><BR>Moreover, there has been a notable decline in investor participation, with delivery volume dropping by 91.38% against the 5-day average. This decline in trading activity may reflect a lack of confidence among investors, despite the stock's recent high performance. The stock is currently trading above its 50-day, 100-day, and 200-day moving averages, but below its 5-day and 20-day moving averages, indicating mixed signals in short-term trading trends.<BR><BR>In summary, while iSERA Lifesciences Ltd has shown remarkable price increases over the longer term, the negative book value, stagnant profits, and declining investor participation suggest underlying weaknesses that could lead to caution among investors.

Who are in the management team of iSERA Lifescienc?

The management team of iSERA Lifescienc includes K L Upadhyaya, Uday Chava, Srinivasa Rao Munnangi, Pittala Sukanya, Naresh Konda, Sakshi Mathur, Sivaiah Kommineni, and Prabhakara Rao Alokam, with roles ranging from directors to company secretary.

The management team of iSERA Lifescienc includes the following individuals:<BR><BR>1. K L Upadhyaya - Independent Director<BR>2. Uday Chava - Independent Director<BR>3. Srinivasa Rao Munnangi - Independent Director<BR>4. Pittala Sukanya - Director<BR>5. Naresh Konda - Whole-time Director<BR>6. Sakshi Mathur - Company Secretary<BR>7. Sivaiah Kommineni - Additional Independent Director<BR>8. Prabhakara Rao Alokam - Director<BR><BR>If you need more specific information about any of these individuals or their roles, feel free to ask!

What does iSERA Lifescienc do?

iSERA Lifesciences Ltd, a Micro Cap company in the IT/ITES sector, was incorporated in 1993 and has undergone several name changes, with its latest financials reporting zero net profit as of June 2026. The company has a market cap of INR 121 Cr and key metrics indicating significant financial challenges.

Overview: <BR>iSERA Lifesciences Ltd operates in the IT/ITES business within the Miscellaneous industry and is categorized as a Micro Cap company.<BR><BR>History: <BR>The company was incorporated on January 27, 1993, originally as 'Lordven Technologies Limited'. It underwent name changes to Aptus Industries Limited in 2011-12 and to Covidh Technologies Limited on April 21, 2014. The latest reported quarter for sales and profit is June 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 121 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 237.00 <BR>Industry P/E: 31 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -1.61 <BR>Return on Equity: -26.00% <BR>Price to Book: -121.01<BR><BR>Contact Details: <BR>Address: B-2 Plot 797/A Sai Krishna Bld, Road No 36 Jubilee Hills Hyderabad Telangana : 500033 <BR>Tel: 91-040-64643093 <BR>Email: cscovidh@gamil.com <BR>Website: http://www.covidh.co.in

Who are the peers of the iSERA Lifescienc?

iSERA Lifescienc's peers include Altius Telecom, Embassy Off.REIT, Mindspace Busine, Inventurus Knowl, Sagility, IDream Film, Kalpa Commer., Focus Suites Sol, and Amsons Apparels. iSERA Lifescienc has the highest 1-year return at 3200.46%, while Kalpa Commer. has the lowest at -29.55%.

Peers: The peers of iSERA Lifescienc are Altius Telecom, Embassy Off.REIT, Mindspace Busine, Inventurus Knowl, Sagility, IDream Film, Kalpa Commer., Focus Suites Sol, and Amsons Apparels.<BR><BR>Quality Snapshot: Excellent management risk is observed at Inventurus Knowl, while Average management risk is found at Altius Telecom, Embassy Off.REIT, Mindspace Busine, Sagility, and the rest. Below Average management risk is noted at Kalpa Commer., and the rest have a management risk that does not qualify. Excellent growth is seen at Inventurus Knowl, while Good growth is found at Sagility, Average growth at Kalpa Commer., and the rest have growth that does not qualify. Capital structure is Excellent for Inventurus Knowl and Sagility, Below Average for Altius Telecom and Kalpa Commer., and the rest have a capital structure that does not qualify.<BR><BR>Return Snapshot: The peer with the highest 1-year return is iSERA Lifescienc at 3200.46%, while the peer with the lowest is Kalpa Commer. at -29.55%. iSERA Lifescienc's 1-year return significantly exceeds all peers. Additionally, Kalpa Commer. and Focus Suites Sol have negative six-month returns.

How big is iSERA Lifescienc?

Summary could not be generated.

As of 31st August, iSERA Lifesciences Ltd has a market capitalization of 121.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, iSERA Lifesciences reported net sales of 19.37 Cr. However, the company experienced a loss of 0.08 Cr during the same period.<BR><BR>The balance sheet data is unavailable for the latest annual period, which limits the ability to provide values for Shareholder's Funds and Total Assets.

Should I buy, sell or hold Covidh Technologies Ltd?

Are Covidh Technologies Ltd latest results good or bad?

Covidh Technologies Ltd's latest results are concerning, showing a 69.34% decline in net sales quarter-on-quarter and a net loss, alongside a negative book value and a drastic drop in promoter holdings. The company's financial health indicates significant distress and a high-risk investment profile.

Covidh Technologies Ltd's latest results indicate significant financial distress. The company reported net sales of ₹1.11 crores for June 2019, which marked a staggering 69.34% decline quarter-on-quarter and a 91.95% drop year-on-year. Furthermore, it recorded a net loss of ₹0.06 crores, with negative operating margins and a negative profit after tax margin.<BR><BR>The company's financial health is further illustrated by its negative book value, with a price-to-book ratio of -24.71x, indicating that its liabilities exceed its assets. This situation has led to a complete absence of institutional investor interest, as there are no holdings from foreign institutional investors, mutual funds, or domestic institutional investors.<BR><BR>Additionally, there has been a dramatic decline in promoter holdings, dropping from 100% to just 3.57% in a short period, which is a significant red flag for potential investors. The extreme volatility in stock price, with a 756.85% increase over six months, does not reflect any underlying business improvement, but rather suggests speculative trading in a micro-cap stock with limited liquidity.<BR><BR>Overall, the financial results and the company's trajectory suggest a concerning outlook, characterized by a lack of sustainable profitability, significant operational struggles, and a high-risk investment profile.

When is the next results date for Covidh Technologies Ltd?

The next results date for Covidh Technologies Ltd is 10 February 2026.

The next results date for Covidh Technologies Ltd is scheduled for 10 February 2026.

How has been the historical performance of Covidh Technolog?

Covidh Technolog has experienced fluctuating financial performance, with net sales declining from INR 33.57 crore in March 2018 to INR 25.69 crore in March 2019, resulting in a profit after tax of -0.04 crore. The company faced rising raw material costs, leading to decreased profitability and negative earnings per share.

Answer:<BR>The historical performance of Covidh Technolog shows a fluctuating trend in net sales and profitability over the years.<BR><BR>Breakdown:<BR>Covidh Technolog's net sales have seen a decline from INR 33.57 crore in March 2018 to INR 25.69 crore in March 2019, following a peak of INR 35.89 crore in March 2014. The total operating income mirrored this trend, dropping from INR 33.57 crore in March 2018 to INR 25.69 crore in March 2019. The company faced significant raw material costs of INR 25.03 crore in March 2019, which contributed to total expenditure of INR 25.20 crore, resulting in a slim operating profit of INR 0.49 crore. However, the profit before tax turned negative at INR -0.02 crore in March 2019, leading to a profit after tax of INR -0.04 crore. This marked a notable decline from a profit after tax of INR 0.01 crore in March 2018. The earnings per share also reflected this downturn, falling to -0.04 in March 2019 from 0.01 in the previous year. Overall, the company's financial metrics indicate a challenging period, with decreasing revenues and profitability.

Is Covidh Technolog overvalued or undervalued?

As of October 24, 2025, Covidh Technolog is considered risky and overvalued with a PE ratio of 47.09 and negative financial metrics, contrasting sharply with its peers, despite a recent short-term stock performance that outpaced the Sensex.

As of 24 October 2025, Covidh Technolog's valuation grade has moved from does not qualify to risky, indicating a significant shift in its perceived investment quality. The company is currently assessed as overvalued, with a PE ratio of 47.09, a negative Price to Book Value of -6.59, and an EV to EBIT of -8.18. These ratios highlight the company's financial struggles and lack of profitability, which are concerning for potential investors.<BR><BR>In comparison to its peers, Covidh Technolog's valuation metrics are starkly unfavorable. For instance, Altius Telecom, categorized as very attractive, boasts a PE ratio of 55.11, while other peers like Embassy Office REIT and Mindspace Business have PE ratios of 25.69 and 55.87, respectively. The stark contrast in these ratios underscores Covidh Technolog's precarious position in the market. Additionally, while the company's stock has outperformed the Sensex in the short term, with a 1-month return of 30.67% compared to the Sensex's 3.05%, the overall valuation concerns suggest that this momentum may not be sustainable.

Who are the top shareholders of the Covidh Technolog?

The top shareholder of Covidh Technolog is Ganapa Narsi Reddy, who owns 100% of the promoter shares. There are no pledged holdings, mutual funds, foreign institutional investors, or significant public shareholders involved.

The top shareholder of Covidh Technolog is Ganapa Narsi Reddy, who holds 100% of the promoter shares. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. Additionally, there are no significant public shareholders or individual investor holdings reported.